↓ Skip to main content

Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging

Overview of attention for article published in BMC Cancer, November 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
9 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
Published in
BMC Cancer, November 2015
DOI 10.1186/s12885-015-1918-1
Pubmed ID
Authors

Jon-Vidar Gaustad, Trude G. Simonsen, Ragnhild Smistad, Catherine S. Wegner, Lise Mari K. Andersen, Einar K. Rofstad

Abstract

Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and diffusion weighted MRI (DW-MRI) in assessing early effects of low dose bevacizumab treatment, and to investigate intratumor heterogeneity in this effect. A-07 and R-18 human melanoma xenografts, showing high and low expression of VEGF-A, respectively, were used as tumor models. Untreated and bevacizumab-treated tumors were subjected to DCE-MRI and DW-MRI before treatment, and twice during a 7-days treatment period. Tumor images of K (trans) (the volume transfer constant of Gd-DOTA) and v e (the fractional distribution volume of Gd-DOTA) were produced by pharmacokinetic analysis of the DCE-MRI data, and tumor images of ADC (the apparent diffusion coefficient) were produced from DW-MRI data. Untreated A-07 tumors showed higher K (trans), v e, and ADC values than untreated R-18 tumors. Untreated tumors showed radial heterogeneity in K (trans), i.e., K (trans) was low in central tumor regions and increased gradually towards the tumor periphery. After the treatment, bevacizumab-treated A-07 tumors showed lower K (trans) values than untreated A-07 tumors. Peripherial tumor regions showed substantial reductions in K (trans), whereas little or no effect was seen in central regions. Consequently, the treatment altered the radial heterogeneity in K (trans). In R-18 tumors, significant changes in K (trans) were not observed. Treatment induced changes in tumor size, v e, and ADC were not seen in any of the tumor lines. Early effects of low dose bevacizumab treatment may be highly heterogeneous within tumors and can be detected with DCE-MRI.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 3 33%
Researcher 2 22%
Professor > Associate Professor 1 11%
Student > Ph. D. Student 1 11%
Unknown 2 22%
Readers by discipline Count As %
Medicine and Dentistry 3 33%
Biochemistry, Genetics and Molecular Biology 2 22%
Physics and Astronomy 1 11%
Agricultural and Biological Sciences 1 11%
Unknown 2 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2015.
All research outputs
#5,613,770
of 7,419,627 outputs
Outputs from BMC Cancer
#2,103
of 3,250 outputs
Outputs of similar age
#195,348
of 285,193 outputs
Outputs of similar age from BMC Cancer
#160
of 269 outputs
Altmetric has tracked 7,419,627 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,250 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,193 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 269 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.